Syncona portfolio company Autolus files for US IPO

FTSE 250 healthcare company Syncona said on Tuesday that its portfolio company, Autolus, has made a confidential submission of a draft registration to the US Securities and Exchange Commission about a potential initial public offering.

Syncona, which is the largest shareholder in Autolus, a clinical-stage biopharmaceutical company specialising in the development and commercialisation of next-generation engineered T-cell therapies, said the process is still in the preliminary stages and an IPO may or may not be pursued.

The group said it is "highly supportive" of Autolus over the long term, in line with its strategy to "build global leaders in life science and deliver transformational treatments to patients".

Healthcare and life science company Arix Biosciences also noted Autulus' potential US IPO on Tuesday.

At 0955 GMT, Syncona shares were up 3.5% to 204.25p.